Key Highlights

  • 4DMedical (ASX: 4DX) fell 14.38% to A$3.245 on 17 July 2026 (confirmed; −A$0.544).
  • Shares resumed trading on 17 July after a 16 July halt tied to an announcement about the proposed AIRCARE for Vets Act (H.R. 9666), which would authorise up to US$20 million for a VA lung-imaging pilot. The bill is proposed only and is not law.
  • For H1 FY26 (six months to 31 December 2025), 4DMedical reported revenue of A$2.85 million (down about 1% year-on-year), with underlying SaaS revenue up 31% and gross margins exceeding 90%.
  • The company held A$56.8 million cash at 31 December 2025, lifted to a pro forma A$206.2 million after a January 2026 placement that raised more than US$100 million.
  • The stock’s 52-week range of roughly A$0.23 to A$7.55 underlines that valuation, not just operations, is driving price action.

Shares in 4DMedical Limited (ASX: 4DX) were sharply lower on Friday, closing down 14.38% to A$3.245 on 17 July 2026 (confirmed closing price; −A$0.544). The pull-back came a day after the respiratory imaging company was placed in a trading halt and then released an announcement addressing proposed United States legislation, the AIRCARE for Vets Act, which names 4D functional lung imaging for a Department of Veterans Affairs pilot. The move continues a period of extreme volatility for one of the ASX’s most talked-about medical-technology names, a stock that has surged more than 1,000% over the past year before repeatedly retracing. For investors, the sell-off reframes a familiar question: does a company generating modest revenue but rapid scan-volume growth justify a market capitalisation in the billions? This article examines the confirmed facts around the move, 4DMedical’s financial position, and and bear arguments.

 

What happened to the shares?

At the close on 17 July 2026, 4DMedical (ASX: 4DX) had fell 14.38% to A$3.245 (−A$0.544). it should not be treated as the day’s official close, which can differ materially once the market settles at 4:00pm AEST.

The decline sits within an exceptionally volatile 12 months. Data aggregators show a 52-week trading range of approximately A$0.23 to A$7.55 and a one-year return of well over 1,000%. The stock reached highs around A$7.55 in April 2026 before falling roughly 55% to about A$3.40 by early May, according to reporting . By early-to-mid July it was changing hands in the region of A$3.70 to A$4.10 ( showed A$4.06 on 9 July 2026). A 14.38% closing fall from those levels is significant in percentage terms but modest relative to the swings 4DX holders have absorbed all year.

In short, this is a stock where daily moves of several per cent have become routine, and a single session should be read in that context.

 

Was there a company-specific catalyst?

Unlike many single-session sell-offs, this one is preceded by a clearly identifiable company event. On 16 July 2026, 4DMedical requested a trading halt under ASX Listing Rule 17.1 pending “a market announcement regarding the potential implications for the company of a bill being proposed in the United States Congress,” with trading to resume by 17 July. The company then disclosed that a bipartisan bill, the AIRCARE for Vets Act (H.R. 9666), introduced by Representatives Juan Ciscomani and Chris Pappas, would direct the Department of Veterans Affairs to establish a pilot program using 4D functional lung imaging, with authorised appropriations of US$20 million. 4DMedical said it was “well-positioned to support such a VA pilot program” given its US commercial footprint and FDA-cleared XV LVAS product.

So the timing is not coincidental: shares resumed and fell on the same day the market digested this news. However, causation should be stated carefully. The announcement itself was arguably favourable — a US company being named in proposed legislation. The negative reaction most plausibly reflects that the bill is only proposed, carries no guarantee of passage, and authorises a relatively small sum, so investors who had bid the stock up ahead of the halt may have judged the outcome less material than hoped. That “sell-the-news” dynamic, layered on an ongoing valuation reset, is interpretation rather than confirmed fact. What is confirmed is the event and its timing; the precise driver of the 14.38% move has not been independently verified.

 

Company overview

4DMedical Limited is a Melbourne-headquartered medical-technology company focused on functional lung imaging. Its core innovation is XV Technology, which converts standard imaging — including routine CT and X-ray — into quantitative, regional measures of how air moves through the lungs, rather than relying solely on static anatomical pictures. The technology is delivered as software-as-a-service (SaaS), meaning hospitals and imaging centres do not need to buy new hardware.

The product portfolio includes XV LVAS (XV Lung Ventilation Analysis Software), the LungQ quantitative CT analysis platform, and CT:VQ, which the company describes as the first and only non-contrast, CT-based ventilation–perfusion imaging cleared by the US Food and Drug Administration (FDA). CT:VQ analyses ventilation and blood flow (perfusion) from a routine CT scan without radioactive tracers, contrast agents or a separate nuclear-medicine appointment.

4DMedical operates across the United States and Australia, with the US positioned as its primary growth market. The company is led by founder and chief executive Dr Andreas Fouras. Reported adopters of its technology include leading US institutions such as Stanford, Cleveland Clinic, UC San Diego and the University of Miami.

 

Latest operational developments

The past year has delivered a dense run of milestones. In the US, CT:VQ secured FDA 510(k) clearance and, critically, US Centers for Medicare & Medicaid Services (CMS) reimbursement of US$650.50 per scan, added to the standard chest CT fee. Reimbursement certainty is a meaningful adoption lever in the US market because it gives hospitals a clear revenue pathway without new capital equipment.

In April 2026, 4DMedical announced an agreement with pharmaceutical major GSK (GlaxoSmithKline) to supply lung-imaging analytics for drug development, alongside UK regulatory clearance and inclusion in the S&P/ASX 200 index. The GSK arrangement is notable because it signals a potential second revenue channel — pharmaceutical clinical trials — beyond hospital diagnostics.

Operationally, the company reported 430 SaaS sites globally at 31 December 2025 (up 43% year-on-year) and 151,905 scans produced in H1 FY26, a 110% increase on the prior corresponding period. The most recent development, the AIRCARE for Vets Act, would — if enacted — formalise long-running US congressional and VA interest in the company’s technology, which 4DMedical says dates back to 2022. As stressed above, that bill remains a proposal.

 

Financial position

4DMedical’s financials frame the valuation debate. For H1 FY26 (the six months to 31 December 2025), the company reported total revenue of A$2.85 million, down roughly 1% on the prior corresponding period. Beneath that headline, management pointed to underlying SaaS revenue growth of 31% and gross margins exceeding 90%, consistent with a software business model.

The statutory result looked alarming at first glance: a reported net loss of A$154.14 million. However, that figure includes a non-cash A$137.8 million remeasurement tied to the equity component of a Pro Medicus debt instrument. On an adjusted basis, 4DMedical reported a net loss of A$16.19 million, down 18% year-on-year — a more useful read of the underlying cash economics.

On the balance sheet, the company held A$56.8 million cash at 31 December 2025, with operating cash outflow of A$12.66 million for the half (an improvement on A$14.15 million a year earlier). Crucially, a January 2026 institutional placement raised more than US$100 million (about A$150 million), lifting pro forma cash to A$206.2 million. At a half-yearly cash burn of roughly A$12–13 million, that pro forma balance implies a multi-year funding runway on current spending — though management has signalled it intends to invest aggressively in US expansion, which would accelerate outflows. Investors should also note that 4DMedical has repeatedly raised equity; market dataed around A$233 million of placements during 2026 at prices between A$3.80 and A$5.90, a dilution and overhang consideration.

 

Sector and macroeconomic context

4DMedical sits at the intersection of three powerful themes: medical imaging, artificial-intelligence-enabled diagnostics, and US healthcare reimbursement. Respiratory disease is a large and growing global burden, and the pitch for functional imaging is that it detects and characterises lung dysfunction earlier and more precisely than conventional tests, using equipment hospitals already own.

The US reimbursement environment is central to the investment case. CMS reimbursement for CT:VQ provides a defined economic incentive for adoption, and the proposed AIRCARE for Vets Act reflects policy-level interest. But US healthcare policy is also a source of risk: reimbursement rates can change, and legislation can stall. Notably, the broader Medicare physician fee schedule for CY2027 and related payment policies were under review around mid-July 2026, a reminder that reimbursement is never static.

For ASX medtech more broadly, 4DX is emblematic of the sector’s boom-and-bust character: small revenues, large addressable markets, heavy reliance on capital markets, and valuations that swing violently on sentiment, index flows and newsflow.

 

Bull case

case rests on a large, under-served market and a differentiated, reimbursed, capital-light product. CT:VQ is positioned as the first and only non-contrast CT-based VQ imaging cleared by the FDA, with CMS reimbursement of US$650.50 per scan already in place — a rare combination of regulatory and payment validation for an ASX small cap. Scan volumes more than doubled year-on-year, SaaS revenue grew 31% underlying, and gross margins above 90% suggest strong operating leverage if adoption scales.

The GSK agreement hints at a pharmaceutical-services revenue stream, and the AIRCARE for Vets Act — if passed — could open a government-backed VA channel. A pro forma cash balance above A$200 million reduces near-term funding risk. Adoption by marquee institutions such as Stanford and Cleveland Clinic lends clinical credibility. Bulls argue that if even a fraction of US chest CT volumes convert to functional analysis, revenue could inflect sharply from a low base.

 

Bear case

The bear case is equally clear. Revenue of A$2.85 million for the half — essentially flat at the headline level — sits against a market capitalisation reported around A$2.45 billion, an extraordinary multiple that leaves little room for disappointment. The stock’s history of running “1,000% ahead of revenues,” as put it, invites the valuation reset already under way, with shares more than halving from their April peak.

Cash burn, while covered for now, depends on continued access to capital, and repeated placements have diluted holders and created an overhang where institutions who bought higher may sell to de-risk. Adoption, though growing fast in scan count, has yet to translate into materially higher revenue — a gap bears attribute to slow reimbursement-to-revenue conversion. Policy dependence cuts both ways: the VA bill is unpassed, and US reimbursement could tighten. For bears, 4DX remains a story stock whose price is set by narrative and flows, not fundamentals.

 

What could move the shares next?

Several identifiable events could drive the price. First, the legislative progress of the AIRCARE for Vets Act — passage, stalling or amendment — would be material given the market clearly reacted to it. Second, the next Appendix 4C quarterly cash-flow report (the June-quarter update would ordinarily be due late July 2026) will show cash receipts, burn and closing cash. Third, any conversion of the GSK relationship or CMS reimbursement into reported revenue growth would test the adoption thesis. Fourth, further capital raisings — or the absence of them — will influence the dilution narrative. Finally, index rebalancing and broader medtech sentiment can amplify moves in a stock this volatile.

 

What investors should monitor

  1. The official 17 July closing price versus the 14.38% closing figure, and whether selling extends.
  2. The status and progress of the AIRCARE for Vets Act (H.R. 9666) through the US Congress.
  3. The next Appendix 4C: quarterly cash receipts, net operating outflow and closing cash.
  4. Reported revenue growth (not just scan volumes) and the SaaS revenue trajectory.
  5. Cash runway and any signals about further equity raisings or dilution.
  6. US CMS reimbursement policy and any changes to CT:VQ economics.
  7. Conversion of the GSK agreement and new hospital sites into recurring revenue.
  8. Insider and substantial-holder activity, and index inclusion/exclusion flows.

 

Conclusion

4DMedical’s 14.38% closing fall on 17 July 2026 is best understood not as a verdict on a single day’s news but as the latest tremor in a year-long tug-of-war between a compelling clinical story and a demanding valuation. The confirmed facts are encouraging on adoption — more than doubling scan volumes, 90%-plus gross margins, FDA clearance, CMS reimbursement and a proposed VA pilot — yet sobering on scale, with half-year revenue under A$3 million against a multi-billion-dollar market capitalisation. The company is well funded for now, but its share price is being driven as much by sentiment, flows and legislative headlines as by its income statement. Whether 4DX rewards or punishes shareholders from here will likely depend on how quickly rising scan volumes and reimbursement translate into revenue that the market can value on fundamentals rather than narrative.